Product
ABBV-951
Aliases
Foscarbidopa, Foslevodopa
5 clinical trials
1 indication
Indication
Parkinson's DiseaseClinical trial
An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson's DiseaseStatus: Active (not recruiting), Estimated PCD: 2025-05-16
Clinical trial
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease PatientsStatus: Completed, Estimated PCD: 2021-09-29
Clinical trial
Parkinson's Disease: A Comparative Study of Levodopa and Carbidopa Bioavailability Following Foslevodopa/Foscarbidopa Infusion at Different Subcutaneous Sites in Parkinson's Disease PatientsStatus: Completed, Estimated PCD: 2023-03-17
Clinical trial
An Open-label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's DiseaseStatus: Active (not recruiting), Estimated PCD: 2025-06-19
Clinical trial
A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's DiseaseStatus: Completed, Estimated PCD: 2022-08-17